Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration

被引：0
|
作者：
Pickar-Oliver, Adrian [1 ]
Nelson, Christopher [1 ]
Bohning, Joel [1 ]
Gemberling, Matthew [1 ]
Bulaklak, Karen [1 ]
Gersbach, Charles A. [1 ]
机构：
[1] Duke Univ, Biomed Engn, Durham, NC USA
来源：
MOLECULAR THERAPY | 2019年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
380
引用
收藏
页码：180 / 181
页数：2
相关论文
共 50 条
  • [41] CRISPR/Cas9 targeted integration prolongs gene expression in vivo
    Stephens, C. J.
    Kashentseva, E.
    Everett, W.
    Kaliberova, L.
    Curiel, D. T.
    HUMAN GENE THERAPY, 2017, 28 (12) : A57 - A58
  • [42] Characterization and Quantification of CRISPR/Cas9-Induced Genomic Alterations and AAV Targeted Integration in Human HSPC
    Tachtsidi, Alexandra
    Corre, Guillaume
    Lacombe, Laurie
    Amendola, Mario
    MOLECULAR THERAPY, 2023, 31 (04) : 267 - 268
  • [43] Development and application of CRISPR/Cas9 technologies in genomic editing
    Zhang, Cui
    Quan, Renfu
    Wang, Jinfu
    HUMAN MOLECULAR GENETICS, 2018, 27 (R2) : R79 - R88
  • [44] Delivery of a Multiplex CRISPR/Cas9 Machinery for the Treatment of Duchenne Muscular Dystrophy with One Single Gene Deleted Adenoviral Vector
    Ehrke-Schulz, Eric
    Mouly, Vincent
    Kley, Rudolph A.
    Ehrhardt, Anja
    MOLECULAR THERAPY, 2018, 26 (05) : 329 - 330
  • [45] Delivery of a multiplex CRISPR/Cas9 machinery for the treatment of Duchenne muscular dystrophy with one single gene deleted adenoviral vector
    Ehrke-Schulz, E.
    Mouly, V.
    Kley, R. A.
    Ehrhardt, A.
    HUMAN GENE THERAPY, 2017, 28 (12) : A40 - A40
  • [46] Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
    Niclas E. Bengtsson
    John K. Hall
    Guy L. Odom
    Michael P. Phelps
    Colin R. Andrus
    R. David Hawkins
    Stephen D. Hauschka
    Joel R. Chamberlain
    Jeffrey S. Chamberlain
    Nature Communications, 8
  • [47] Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
    Bengtsson, Niclas E.
    Hall, John K.
    Odom, Guy L.
    Phelps, Michael P.
    Andrus, Colin R.
    Hawkins, R. David
    Hauschka, Stephen D.
    Chamberlain, Joel R.
    Chamberlain, Jeffrey S.
    NATURE COMMUNICATIONS, 2017, 8
  • [48] AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities
    Kabadi, Ami M.
    Mejia-Guerra, Maria Katherine
    Graef, John D.
    Khan, Sohrab Z.
    Walton, Eric M.
    Wang, Xinzhu
    Gersbach, Charles A.
    Potter, Rachael
    CURRENT OPINION IN BIOMEDICAL ENGINEERING, 2024, 29
  • [49] Correction of the Dystrophin Gene By the CRISPR/Cas9 System in a Mouse Model of Muscular Dystrophy
    Nelson, Christopher E.
    Ousterout, David G.
    Robinson-Hamm, Jacqueline N.
    Moreb, Eirik A.
    Castellanos, Ruth M.
    Ran, Fei Ann
    Yan, Winston
    Zhang, Feng
    Asokan, Aravind
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2015, 23 : S157 - S158
  • [50] CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy
    Wang, Dan-Ni
    Wang, Zhi-Qiang
    Jin, Ming
    Lin, Min-Ting
    Wang, Ning
    GENE THERAPY, 2022, 29 (12) : 730 - 737
12345